Background {#Sec1}
==========

Glucagon-like peptide-1 (GLP-1) receptor agonists are a relatively new class of incretin-based agents for the treatment of type 2 diabetes mellitus that lower blood glucose \[[@CR1], [@CR2]\], reduce body weight \[[@CR3]\], and possibly reduce cardiovascular risk compared to placebo \[[@CR4], [@CR5]\]. The American Diabetes Association and the European Association for the Study of Diabetes recommend GLP-1 agonists as a second-line treatment option for type 2 diabetes \[[@CR6]\].

In 2014, the US Food and Drug Administration raised concerns regarding heart failure risk with one dipeptidyl peptidase-4 (DPP-4) inhibitor, saxagliptin \[[@CR7]\]. These concerns followed publication of studies that reported increased risk of hospitalization for heart failure in patients using DPP-4 inhibitors \[[@CR8]--[@CR10]\]. These observations raise the possibility that GLP-1 agonists, which share a similar pharmacological mechanism with DPP-4 inhibitors, might also cause heart failure.

Animal studies have shown that the GLP-1 agonist liraglutide can activate cytoprotective pathways in the heart, and improve outcomes after experimental myocardial infarction in mice \[[@CR11]\]. Early clinical studies also suggested that GLP-1 agonists have positive effects on cardiovascular biomarkers, such as high-sensitivity C-reactive protein and plasminogen activator inhibitor-1 \[[@CR12], [@CR13]\], and improve regional and overall left ventricular function in patients with acute myocardial infarction and severe systolic dysfunction after successful primary angioplasty \[[@CR14]\].

Clinical trial results often, however, prove inconsistent with laboratory and surrogate outcome studies, and emerging randomized trials and observational studies have, reported inconsistent results \[[@CR15]--[@CR19]\]. We therefore undertook a systematic review to address the effect of GLP-1 agonists on heart failure or hospitalization for heart failure in patients with type 2 diabetes.

Methods {#Sec2}
=======

We followed the PRISMA and MOOSE guidelines for conducting and reporting systematic reviews and meta-analyses of randomized controlled trials (RCTs) and observational studies \[[@CR20], [@CR21]\].

Data sources and search strategy {#Sec3}
--------------------------------

We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to 25 June, 2015. We used both MeSH and free text terms to identify relevant articles. An information expert (DP) developed each database-specific search strategy (Additional file [1](#MOESM1){ref-type="media"}). We also searched ClinicalTrials.gov as well as conference abstracts published by the American Diabetes Association, European Association for the Study of Diabetes, and European Society of Cardiology for additional eligible studies and trial information.

Eligibility criteria {#Sec4}
--------------------

We included RCTs, cohort studies, or case--control studies that compared GLP-1 agonists against placebo, lifestyle modification, or active anti-hyperglycemic medication in adult type 2 diabetes patients, reported ≥ 12 weeks follow-up data (not applicable to case--control studies), and explicitly reported the outcome of heart failure or hospitalization for heart failure.

Study selection {#Sec5}
---------------

Paired reviewers, trained in research methods, independently screened titles/abstracts and then full texts for eligibility, assessed risk of bias, and collected data from each included study, using pilot-tested standardized forms with corresponding detailed instructions. Any disagreement between the two reviewers was resolved through discussion or adjudication by a third reviewer (XS).

Risk of bias and quality of evidence assessment {#Sec6}
-----------------------------------------------

We assessed the risk of bias of RCTs according to modified version of the Cochrane Collaboration's tool \[[@CR22], [@CR23]\] in which the response options are \"probably yes\" and \"probably no\" instead of \"unclear\"; the approach has shown to be reliable and valid for blinding \[[@CR24]\]. The items include randomization sequence generation; allocation concealment; blinding of participants, caregivers, outcome assessors (i.e., heart failure or hospitalization for heart failure), and outcome adjudicators; prognostic balance between treatment groups; and incomplete outcome data.

We used a modified version of the Newcastle -- Ottawa Quality Assessment Scale \[[@CR25]--[@CR27]\] for assessing risk of bias of observational studies. Specifically, we removed two items "representativeness of the exposed cohort" and "was follow-up long enough for outcomes to occur" that we judge related to applicability, and added two items - ascertainment of type 2 diabetes and adjustment for potential confounding factors. We planned to assess for risk of publication bias, but were unable to do so due to low power of the relevant tests in the presence of low events rates.

We rated the quality of evidence for heart failure and hospitalization for heart failure as high, moderate, low, or very low using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology \[[@CR28]--[@CR34]\].

Data extraction {#Sec7}
---------------

We collected the following information from each eligible studies: study characteristics (e.g., author name, year of publication, study design, sample size, length of follow-up), patient characteristics (e.g., gender, age, diabetes duration, body mass index (BMI), baseline HbA1c level), interventions (e.g., details of GLP-1 agonists therapy and control group), and outcomes (number of events and patients included for analyses in each group, as well as adjusted data if available). For trials with multiple reports, we collated all data into a single study \[[@CR35]\]; for trials with reports both from ClincialTrials.gov and journal publications, we carefully checked the data for consistency; for trials reporting outcome data of multiple follow up points, we used the data with longest follow up. For observational studies, we also collected information on data source, methods used to control confounding, and reported adjustment factors.

Statistical analysis {#Sec8}
--------------------

We analyzed RCTs and observational studies separately. We did not combine the outcomes of heart failure and hospitalization for heart failure, as hospitalization for heart failure is likely more serious and of greater importance to patients than heart failure not requiring hospitalization.

We assessed statistical heterogeneity with the Cochran chi-square test and I-squared statistic. We used Peto's method to pool data from RCTs \[[@CR36], [@CR37]\] using random effects models and reported pooled Peto odds ratios (ORs) and associated 95 % confidence intervals (CIs). We conducted four a priori subgroup analyses to explore heterogeneity associated with our pooled estimates: (1) type of control (placebo vs. active treatment), (2) length of follow up (52 weeks or shorter vs. over 52 weeks), (3) mode of therapy (GLP-1 agonists monotherapy vs. add-on/combination therapy), and (4) individual GLP-1 agonists agents (different GLP-1 agonists agents vs. control). We also carried out sensitivity analyses to explore the robustness of our findings using different effect measures, pooling methods, and statistical models.

We pooled adjusted estimates of heart failure from cohort studies using random effects model due to significant variations in the comparison and patient populations among eligible studies.

### Ethics {#Sec9}

Ethical approval was not necessary as this study is a Systematic Review and Meta-Analysis.

Results {#Sec10}
=======

Study selection {#Sec11}
---------------

Our literature search yielded 11,441 reports; 821 were potentially eligible after title and abstract screening, and 25 studies proved eligible after full text screening. These included 21 RCTs involving 18,270 patients from 30 reports \[[@CR15], [@CR16], [@CR38]--[@CR65]\] and four observational studies \[[@CR17]--[@CR19], [@CR66]\] involving 111,029 patients (three cohort studies and one nested case--control study) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow chart of article selection

Evidence from randomized controlled trials {#Sec12}
------------------------------------------

### RCTs reporting heart failure {#Sec13}

Twenty trials reported on heart failure; 18 (80 %) were multi-center studies, and 18 (90 %) were clearly labeled as phase III trials. These trials enrolled 46 to 1,091 patients (total 12,199); the mean age of patients ranged 52.9 to 67.2 years old, mean BMI 25.6 to 33.3 kg/m^2^, mean baseline HbA1c 7.6 to 8.5 %, mean FPG 7.1 to 10.0 mmol/L, and mean or median duration of diabetes was 2.6 to 11.5 years (Table [1](#Tab1){ref-type="table"}). Five used GLP-1 agonists as monotherapy, 15 as add-on or combination therapy (Table [2](#Tab2){ref-type="table"}). The length of follow-up ranged from 16 to 164 weeks (median 52; 10 trials followed patients for \> 52 weeks).Table 1Baseline characteristics of included randomized controlled trialsStudyInternational studyNumber of countries involvedNumber of study sitesStudy phaseTotal number of patients randomizedLength of follow up (weeks)Male (*n*,%)Mean age (years)Mean BMI (kg/m^2^)Mean HbA1c (%)Mean FPG (mmol/L)Mean diabetes duration (years)Trials reporting heart failure Inagaki 2012 \[[@CR38], [@CR39]\]No1NRIII42726290 (67.9)56.826.18.5NR9.0 NCT00294723 2010 \[[@CR40], [@CR41]\]Yes2138III746104371 (49.7)53.033.18.39.45.4 NCT00318461 2010 \[[@CR42]--[@CR44]\]Yes21170III1091104635 (58.2)56.731.08.410.07.6 NCT00360334 2009 \[[@CR45]\]No135III23526160 (68.4)56.6NRNRNR6.0 NCT00614120 2010 \[[@CR46]\]Yes351III92916514 (55.3)53.325.6NRNR7.5 NCT00701935 2013 \[[@CR47]\]Yes217II802642 (52.5)58.1NRNRNRNR NCT00838903 2014 \[[@CR48], [@CR49]\]Yes10289III1049164482 (47.6)54.532.68.19.26.0 NCT00838916 2014 \[[@CR50], [@CR51]\]Yes4222III779164418 (56.1)55.533.18.39.58.8 NCT00839527 2014 \[[@CR52]\]Yes9358III685164353 (53.2)55.2NRNRNRNR NCT00849017 2014 \[[@CR53]\]Yes3262III309164166 (55.1)52.9NRNRNRNR NCT00849056 2014 \[[@CR54]\]Yes6331III310156180 (59.8)55.0NRNRNRNR NCT00855439 2015 \[[@CR55]\]No11NR468226 (56.5)53.0NRNRNRNR NCT00960661 2013 \[[@CR56], [@CR57]\]Yes17108III63730261 (51.2)59.532.58.27.111.5^a^ NCT01064687 2015 \[[@CR58]\]Yes389III97826570 (58.4)55.733.28.19.08.8 NCT01075282 2015 \[[@CR59]\]Yes2078III81078353 (51.3)56.731.68.19.19.1 NCT01126580 2015 \[[@CR60], [@CR61]\]Yes1991III80756353 (43.7)55.633.37.69.02.6 NCT01191268 2014 \[[@CR62]\]Yes16101III88452473 (53.5)59.432.58.5NR12.7 NCT01512108 2014 \[[@CR63]\]No136III36352262 (72.8)59.5NR8.18.8NR NCT01620489 2014 \[[@CR64]\]Yes650III27726140 (50.5)67.2NRNRNRNR Pratley 2013 \[[@CR65]\]Yes17130III76024362 (48.9)56.432.78.310.08.8Trials reporting hospitalization for heart failure Bentley-Lewis 2015 (ELIXA) \[[@CR15], [@CR16]\]Yes49NRIII6068108^b^4207 (69.3)60.330.27.78.29.3*BMI* body mass index, *FPG* fasting plasma glucose, *NR* not reported^a^median diabetes duration (years); ^b^median follow up time (weeks)Table 2Intervention tested and event rates in randomized controlled trialsStudyMedications used across groupsIncretinControlDuration of treatment (weeks)TypeEventsTypeEventsTrials reporting heart failure Inagaki 2012 \[[@CR38], [@CR39]\]BG or BG + TZDExenatide1/215Insulin glargine0/21226 NCT00294723 2010 \[[@CR40], [@CR41]\]NoneLiraglutide1/497Glimepiride0/248104 NCT00318461 2010 \[[@CR42]--[@CR44]\]MetforminLiraglutide1/724Placebo0/121104Liraglutide1/724Glimepiride0/242 NCT00360334 2009 \[[@CR45]\]OADsExenatide0/118Insulin glargine1/11626 NCT00614120 2010 \[[@CR46]\]MerforminLiraglutide1/697Glimepiride0/23116 NCT00701935 2013 \[[@CR47]\]NoneExenatide0/43Placebo1/3726 NCT00838903 2014 \[[@CR48], [@CR49]\]MetforminAlbiglutide2/302Placebo0/101156Albiglutide2/302Glimepiride1/307 NCT00838916 2014 \[[@CR50], [@CR51]\]Metformin ± SUAlbiglutide2/504Insulin glargine2/241156 NCT00839527 2014 \[[@CR52]\]Metformin + glimepirideAlbiglutide0/271Placebo1/115164Albiglutide0/271Pioglitazone4/277 NCT00849017 2014 \[[@CR53]\]NoneAlbiglutide1/200Placebo2/101164 NCT00849056 2014 \[[@CR54]\]Pioglitazone ± MetforminAlbiglutide0/150Placebo1/151156 NCT00855439 2015 \[[@CR55]\]Other diabetes medicationsExenatide1/22Glargine1/2478 NCT00960661 2013 \[[@CR56], [@CR57]\]Insulin glargine + metforminExenatide0/315Insulin lispro1/31230 NCT01064687 2015 \[[@CR58]\]Metformin and pioglitazoneDulaglutide1/559Placebo0/14126Exenatide0/278Placebo0/141 NCT01075282 2015 \[[@CR59]\]Metformin and glimepirideDulaglutide3/545Insulin glargine1/26278 NCT01126580 2015 \[[@CR60], [@CR61]\]NoneDulaglutide1/539Metformin0/26852 NCT01191268 2014 \[[@CR62]\]Insulin lisproDulaglutide0/588Insulin glargine1/29652 NCT01512108 2014 \[[@CR63]\]NoneLiraglutide1/240Additional OAD0/12052 NCT01620489 2014 \[[@CR64]\]OAD and/or insulinLiraglutide1/140Placebo0/13726 Pratley 2013 \[[@CR65]\]SU ± metforminTaspoglutide0/494Pioglitazone2/25724Trials reporting hospitalization for heart failure Bentley-Lewis 2015 (ELIXA) \[[@CR15], [@CR16]\]Metformin, SU, glinide, TZD, insulin, metformin and SU, insulin and OADs, or other diabetes medicationsLixisenatide122/3034Placebo127/3034100*BG* biguanide, *TZD* thiazolidinedione, *OADs* oral antidiabetic drugs, *SU* sulfonylurea

All the trials reported industry funding; 18 were identified from ClinicalTrials.gov, of which 12 had no corresponding journal publications. Because of the limited information provided in the trial registry, we were unable to adequately assess the risk of bias for these 12 trials. Additional file [2](#MOESM2){ref-type="media"} presents the details of the assessment for risk of bias. The baseline demographics and clinical characteristics of patients in each included trials were generally balanced between groups. The overall risk bias of eligible RCTs was moderate.

Twenty trials reported 36 heart failure events in 11,758 patients using at least one medication (raw event rate 0.3 %). The pooling of those trials showed no statistically significant difference in the risk of heart failure between GLP-1 agonists treatment and control (17/7,441 in GLP-1 agonists and 19/4,317 control; OR 0.62, 95 % CI 0.31 to 1.22, I-square = 0 %; risk difference (RD) 19 fewer, 95 % CI 34 fewer to 11 more per 1000 over 5 years) (Fig. [2](#Fig2){ref-type="fig"}). We rated the quality of evidence as low because of risk of bias and imprecision (Table [3](#Tab3){ref-type="table"}).Fig. 2Risk of heart failure in patients who received GLP-1 agonists versus control from randomized controlled trialsTable 3GRADE evidence profile of glucagon-like peptide-1 receptor agonists and risk of heart failure in type 2 diabetesQuality assessmentSummary of findingsQuality of evidenceStudy event ratesRelative risk (95 % CI)Anticipated absolute effects (5-year time frame)No of participants (studies)\
Follow-up timeRisk of biasInconsistencyIndirectnessImprecisionPublication biasWith controlWith GLP-1 agonistsRisk with controlRisk difference with GLP-1 agonists (95 % CI)Heart failure 11758\
 (20)\
 16-164 weeksSerious limitation due to risk of bias^a^No serious limitationsNo serious limitationsSerious limitation,\
confidence interval includes important benefit and harmUndetected19/4317 (0.44 %)17/7441 (0.23 %)OR 0.62\
(0.31 to 1.22)50 per 1000^b^19 fewer per 1000 (34 fewer to 11 more)⊕ ⊕ ΟΟ\
**Low** due to risk of bias and imprecisionHospitalization for heart failure 6068\
 (1)\
 2.1 yearsNo serious limitationsNo serious limitationsNo serious limitationsSerious limitation,\
confidence interval includes important benefit and harmUndetected127/3034\
4.2 %122/3034\
4 %HR 0.96\
(0.75 to 1.23)100 per 1000^c^4 fewer per 1000 (25 fewer to 23 more)⊕ ⊕ ⊕Ο\
**Moderate** due to imprecision*GLP-1* glucagon-like peptide-1^a^Several trials probably had risk of bias on random sequence generation, allocation concealment and blinding (Additional file [2](#MOESM2){ref-type="media"}), and the follow up (median of 52 weeks) was not long enough for heart failure to occur in patients with low risk of cardiovascular disease^b^Baseline risk estimate for heart failure in a 5-year time frame comes from the control arm of the cohort study we identified to best represent our target population (Kannan 2015 \[[@CR17]\]), with 528 events of heart failure in 13,185 participants (4.0 %) at four year follow up across control and intervention arm^c^Baseline risk estimate for hospitalization for heart failure in 5-year time frame comes from the control arm of the only included ELIXA trial \[[@CR16]\] we identified to best represent our target population with 127 events in 3034 participants (42 per 1000) over a 2.1 year follow up period, in the absence of observational studies providing more credible baseline risk estimates

Subgroup analysis by type of control (interaction *p* = 0.79), mode of therapy (interaction *p* = 0.84) and length of follow up (interaction *p* = 0.64) showed no differential treatment effects (Additional files [3](#MOESM3){ref-type="media"}, [4](#MOESM4){ref-type="media"}, [5](#MOESM5){ref-type="media"} and [6](#MOESM6){ref-type="media"}). The subgroup analysis of heart failure risk by individual GLP-1 agonists agents suggested a possibility of differential treatment effect across individual agents (interaction *p* = 0.07), with liraglutide associated with a non-significant increased risk for heart failure (OR 4.85, 95 % CI 0.75 to 31.36); this finding was however based on a limited number of events (five in total) and characterized with very wide confidence interval.

Sensitivity analysis using alternative effect measures, statistical methods, and analysis models did not show important changes in pooled effects.

### Trials reporting hospitalization for heart failure {#Sec14}

The Evaluation of LIXisenatide in Acute Coronary Syndrome (ELIXA) trial, designed to assess the cardiovascular safety of lixisenatide, reported hospitalization for heart failure \[[@CR15], [@CR16]\] (Table [1](#Tab1){ref-type="table"}). The ELIXA trial randomized 6,068 patients with type 2 diabetes and a recent acute coronary syndrome to lixisenatide or placebo, with a median of follow up of 2.1 years. In this trial, 122 patients were hospitalized for heart failure among 3,034 patients taking lixisenatide (4.0 %) and 127 in 3034 patients taking placebo (4.2 %), and no statistically significant difference was present between the groups (hazard ratio (HR) 0.96, 95 % CI 0.75 to 1.23; RD 4 fewer, 95 % CI 25 fewer to 23 more per 1000 over 5 years). The trial authors\' subgroup analysis by type of history of heart failure showed no differential treatment effects (lixisenatide vs. placebo: patients with history of heart failure: HR 0.93, 95%CI 0.66 to 1.30; patients with no history of heart failure: HR 0.97, 95 % CI 0.67 to 1.40). We rated the quality of evidence as moderate (Table [3](#Tab3){ref-type="table"}).

Evidence from observational studies {#Sec15}
-----------------------------------

### Studies reporting heart failure {#Sec16}

Three cohort studies \[[@CR17], [@CR18], [@CR66]\] reported heart failure. Of these, one prospectively designed study \[[@CR66]\] examined exenatide versus basal insulin; the other two \[[@CR17], [@CR18]\] -- retrospective in design - assessed GLP-1 agonists versus sulfonylureas, and exenatide or exenatide plus insulin versus insulin (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}). The sample sizes ranged from 882 to 39,225, and length of follow up ranged from 1 to 4 years. The mean age ranged from 58.28 to 62.5 years, BMI 32.6 to 35.3 kg/m^2^, and mean baseline HbA1c 7.9 to 8.9 %.Table 4Characteristics of included observational studiesStudyStudy designData sourceCountries involvedFundingTotal number of patientsFollow up (years)Male (*n*, %)Mean age (years)Mean BMI (kg/m^2^)Mean HbA1c (%)Mean FPG (mmol/L)Mean diabetes duration (years)CVD at baselineStudies reporting heart failure NCT01060059 2013 \[[@CR66]\]Prospective cohort studyReal world dataItalyPrivate for-profit funding8821493 (55.9)62.5NR8.9NRNRNR Kannan 2015 \[[@CR17]\]^a^Retrospective cohort studyElectronic health recordsU.S.No funding13,1854^b^7827 (54.6)60.632.6^c^NRNRNRIncluded patients had no history of CVD or congestive heart failure at baseline Paul 2015 \[[@CR18]\]Retrospective cohort studyClaims dataU.S.NR39,2253.5^b^18093 (46.1)58.235.37.9NR1.3Included patients had CVD or no CVD at baselineStudies reporting hospitalization for heart failure Yu 2015 \[[@CR19]\]^a^Nested case--control studyElectronic medical recordsUKPublic funding57,737NA32795 (56.8)61.6NRNRNR2.3Included patients had CVD or no CVD at baseline^a^These two studies accessed incretin agents (both glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors) and the risk of heart failure, so the data above were the characteristics of total patients included*BMI* body mass index, *FPG* fasting plasma glucose, *CVD* cardiovascular disease, *NR* not reported, *NA* not applicable^b^median follow-up (years); ^c^Median BMI (kg/m^2^)Table 5Exposures, outcomes, and results of observational studiesStudyExposure of interestControl groupNumber of events or casesTotal number of analyzed patientsAdjusted estimates (95 % CI)Adjusted covariateStudies reporting heart failure Kannan 2015 \[[@CR17]\]GPL-1 agonists (combined with metformine)Sulfonylureas (combined with metformine)528^a^13,185 (55,110 person years)^a^HR 1.10 (0.99 to 1.22)Age, sex, race, BMI, number of encounters, median household income, smoking status, systolic and diastolic blood pressure, hypertension, dyslipidemia, cerebral vascular event, presence of neuropathy, retinopathy, dementia, chronic obstructive pulmonary disease, cancer, atrial fibrillation, anti-hypertensive medications, lipid lowering agents, anti-platelet agents and propensity for being on metformin and sulfonylureas at baseline, lipid profile, estimated glomerular filtration rate Paul 2015 \[[@CR18]\]Exenatide/exenatide + insulinInsulin233839,225Exenatide vs insulin: HR 0.34 (0.22, 0.52)\
Exenatide + insulin vs insulin: HR 0.40 (0.32, 0.50)\
Without previous CVD:\
 Exenatide vs insulin: HR 0.34 (0.22, 0.52)\
 Exenatide + insulin vs insulin: HR 0.40 (0.32, 0.50)\
Without previous CVD & renal diseases:\
 Exenatide vs insulin: HR 0.32 (0.21, 0.50)\
 Exenatide + insulin vs insulin: HR 0.35 (0.28, 0.45)Gender, ethnicity, age at the start of cohort, BMI, HbA1c, systolic and diastolic blood pressure on the index date, history of cardiovascular disease, any renal disease prior to index date or during follow-up, use of metformin, sulfonylurea, cardioprotective medications or antihypertensive medications, and the duration of diabetes NCT01060059 2013 \[[@CR66]\]ExenatideBasal insulin2882NRNRStudies reporting hospitalization for heart failure Yu 2015 \[[@CR19]\]GLP-1 agonists (exenatide and liraglutide, alone or incombination with other antidiabetic drugs)Other oral antidiabetic drugs1,118^a^18,744^a^OR 0.67 (0.32 to 1.42)Sex, BMI, excessive alcohol use, smoking status, HbA1c level, comorbidities (neuropathy, renal disease, retinopathy, atrial fibrillation, cancer \[other than nonmelanoma skin cancer\], chronic obstructive pulmonary disease, coronary artery disease, dyslipidemia, hypertension, previous myocardial infarction, peripheral arteriopathy, previous coronary revascularization, peripheral vascular disease, and previous stroke), number of prescriptions, number of physician visits, and use of the following drugs in the year prior to cohort entry: angiotensin converting enzyme inhibitors, angiotensin receptor blockers, β-blockers, calcium channel blockers, diuretics, fibrates, statins, aspirin, and other nonsteroidal anti-inflammatory drugs^a^These two studies accessed incretin agents and the risk of heart failure, and the data of events/cases and total number of analyzed patients regarding glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors were not reported separately, so the data above were the data of total study patients*CI* confidence interval, *NR* not reported, *HR* hazard ratio, *OR* odds ratio, *CVD* cardiovascular disease, *BMI* body mass index

The three studies used electronic heath records or claims data for their analyses. Type 2 diabetes patients were ascertained by specialists in outpatient setting in the prospective cohort study \[[@CR66]\]; the other two retrospective cohort study \[[@CR17], [@CR18]\] did not explicitly state the ascertainment of type 2 diabetes. None of these studies mentioned the ascertainment of exposure to GLP-1 agonist agents and other confounding variables. Only one study \[[@CR17]\] demonstrated that outcome of interest was not present at start of study, and mentioned the method used to assess the outcome of interest. Two studies \[[@CR18], [@CR19]\] used advanced statistical model to control for the influence of confounding factors. Overall, the risk of bias associated with these studies was moderate to high (Additional file [7](#MOESM7){ref-type="media"}).

All three studies reported raw data, for a total of 2,868 heart failures among 53,292 patients (raw event rate 5.4 %); two retrospective cohort studies \[[@CR17], [@CR18]\] reported adjusted effect estimates (Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}). The prospective cohort study \[[@CR66]\], enrolling 882 patients with one year follow-up, found that two patients (2/438) in the basal insulin had heart failure events and no patients (0/444) in exenatide group. One retrospective cohort study \[[@CR17]\], including 13,185 patients and with a median follow-up of four years, reported that GLP-1 agonists were associated with a non-significant increase in heart failure versus sulfonylureas (adjusted HR 1.10, 95 % CI 0.99 to 1.22). The other retrospective cohort study \[[@CR18]\], involving 39,225 patients and with a median follow-up of 3.5 years, found that both exenatide and exenatide plus insulin were associated with a lower risk of heart failure versus insulin alone (adjusted HR 0.34, 95 % CI 0.22 to 0.52; adjusted HR 0.40, 95 % CI 0.32 to 0.50, respectively, Fig. [3](#Fig3){ref-type="fig"}). Using GRADE, we rated the quality of evidence in the included studies as very low, due to risk of bias, indirectness and heterogeneity in addition to the inherent risk for confounding associated with observational studies.Table 6Risk of heart failure or hospitalization for heart failure among patients with type 2 diabetes receiving glucagon-like peptide-1 receptor agonists treatmentComparisonNumber of studies (Events or cases, patients)GLP-1 agonists (events/patients)Control (events/patients)Effect Estimate (95%CI)Cardiovascular morbidities at baseline1. Heart failure Randomized controlled trials  GLP-1 agonists vs. control20 (36, 11758)17/744119/4317Pooled OR 0.62 (0.31 to 1.22)Typically without CVD at baseline Cohort studies  GLP-1 agonists vs. SU1 (528, 13185)NRNRAdjusted HR 1.10 (0.99 to 1.22)No history of CVD or congestive heart failure at baseline  Exenatide vs. insulin Exenatide + insulin vs. insulin1 (2338, 39225)49/2804\
195/78702094/28551\
2094/28551Adjusted HR 0.34 (0.22, 0.52)\
Adjusted HR 0.40 (0.32, 0.50)With or without CVD at baseline  Exenatide vs. basal insulin1 (2, 882)0/4442/438Unadjusted OR 0.13 (0.01 to 2.13)NR2. Hospitalization for heart failure Randomized controlled trials  Lixisenatide vs. placebo1 (249, 6068)122/3034127/3034Pooled Adjusted HR 0.96 (0.75, 1.23)Acute coronary syndrome Nested case--control studies  GLP-1 agonists vs. other OADs1 (1118, 18744)Adjusted OR 0.67 (0.32 to 1.42)With or without CVD at baseline*GLP-1* glucagon-like peptide-1, *CVD* cardiovascular disease, *SU* sulfonylurea, *OR* odds ratio, *HR* hazard ratio, *NR* not reported, *OADs* oral antidiabetic drugsFig. 3Risk of heart failure in patients who received GLP-1 agonists versus control based on adjusted data of observational studies

### Studies reporting hospitalization for heart failure {#Sec17}

One nested case--control study \[[@CR19]\] assessed with GLP-1 agonists versus other oral anti-hyperglycemic drugs (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}). This study included 57,737 patients, with a mean age of 61.6 years and mean duration of diabetes 2.3 years. The methodological details regarding the control for bias are provided in Additional file [8](#MOESM8){ref-type="media"}. This study included 1118 cases and 17,626 matched controls and found that, compared to the use of other anti-hyperglycemic drugs, GLP-1agonists were not associated with increased risk of hospitalization for congestive heart failure (adjusted OR 0.67, 95 % CI 0.32 to 1.42). Using GRADE, we rated the quality of evidence as very low, due to risk of bias and imprecision in addition to the inherent risk for confounding associated with observational studies.

Discussion {#Sec18}
==========

Main findings {#Sec19}
-------------

Our pooled analysis of 20 RCTs addressing use of GLP-1 agonists for type 2 diabetes found moderate quality evidence suggesting no increase in heart failure. The only RCT provided high quality evidence that lixisenatide did not increase the risk of hospitalization due to heart failure. Though the four observational studies provide only very low quality evidence, their results are consistent with those from the randomized trials.

Strengths and limitations {#Sec20}
-------------------------

We are the first to systematically review the evidence regarding GLP-1 agonists for type 2 diabetes and risk of heart failure. Our study has several strengths. First, we used rigorous methods to systematically identify both randomized and observational studies that reported data to inform this issue, including a large number of trials that were not published in journals. Second, we carefully checked the data reported in ClinicalTrials.gov and journal publications for consistency to ensure accuracy of the data. Third, we analysed the data on heart failure and hospitalization for heart failure separately, because those outcomes are likely to be of different importance to patients. Fourth, we used the GRADE approach to assess the quality of evidence on an outcome-by-outcome basis.

Our study also has limitations. First, the available evidence is not strength to give definitive answer for this question, since the included RCTs reported few heart failure events and the follow-up was not enough for heart failure to occur, and much findings came from observational studies of very low quality evidence. Second, we have included some observational studies at moderate to high risk of bias. This has made the inference about the effects of GLP-1 agonists challenging. Third, the diversity of observational studies also made our analysis of the evidence difficult. One retrospective cohort study \[[@CR18]\], assessing exenatide and/or insulin on heart failure outcome, included patients with heart failure at baseline, and the proportion of patients with history of heart failure was higher in the insulin group (3.2 %) than in the exenatide group (1.7 %) and exenatide + insulin group (2.4 %), which made the finding from this study biased.

Other researches {#Sec21}
----------------

Ours is the first systematic review addressing the impact of GLP-1 agonists on heart failure. There is some evidence from human studies that GLP-1 agonists might provide protection against heart failure: preliminary study \[[@CR67]\] showed that GLP-1 treatment might have a trend towards improvement of cardiac function in type 2 diabetes patients with stable heart failure; intrinsic GLP-1 expression has been shown to compensatorily upregulate in patients with left heart failure \[[@CR68]\]; and GLP-1 agonists are also shown to be associated with a modest increase of ejection fraction in diabetic patients \[[@CR69]\]. A recent meta-analysis of RCTs \[[@CR70]\] found that GLP-1 agonists were associated with a modest reduction in blood pressure and a slight increase in heart rate. These biological studies suggest that GLP-1 agonists might, if anything, reduce the incidence of heart failure. Though results of RCTs fail to show this decrease, confidence intervals do not exclude the possibility of a modest reduction.

Conclusions {#Sec22}
===========

The current evidence suggests that GLP-1 agonists do not increase the risk of heart failure or hospitalization for heart failure. The current body of evidence, however, is not definitive. More carefully designed, conducted, adequately powered trials and observational studies are warranted to confirm the effects of GLP-1 agonists on incidence of heart failure and hospitalization for heart failure. Future studies should also examine whether the effects of GLP-1 agonists on heart failure are affected by patient\'s baseline risk of cardiovascular disease.
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